Search Results for: "amgen v mylan"

BPCIA Litigation Roundup (Fall 2017)

Below is our fall update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, Fall 2016, Midwinter 2017, Spring 2017, Summer 2017).

Read More

New BPCIA Litigation: Amgen v. Mylan (W.D. Pa.)

On Friday, Amgen filed a complaint for patent infringement under the BPCIA against yet another developer of a biosimilar of Neulasta® (pegfilgrastim).  Amgen has sued Mylan in the Western District of Pennsylvania for infringement of U.S. Patent Nos. 8,273,707 and 9,643,997, which Amgen alleges “claim methods of purifying proteins used…

Read More